Food and Drug Administration

Endocrinologic & Metabolic Drugs Advisory Committee

January 14, 2003

Slides

Replagal™

Disclaimer

The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Replagal BLA 103977 Transkaryotic Therapeis, Inc. (HTM) (PPT)

Replagal™ Gene Activated Human aGalactosidase, Introduction, FDA (HTM) (PPT)

Agalsidase Alfa for Treatment of Fabry Disease, Transkaryotic Therapies, Inc. (HTM) (PPT)